Clinical trials: Gastrointestinal and Digestive Disorder
Hepatitis B, Polio
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three dose (2-3-4 month) primary series.
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00315055
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-IPV//PRP~T combined, Hepatitis B vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Neuroendocrine Tumor, Gastrointestinal Neoplasm
A Study of XmAb®18087 in Subjects With NET and GIST
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK…
- Trial name
- NCT03411915
- Testing
- XmAb18087
- Where
- 16 sites in United States
- Volunteers
- 62 people
- Sponsor
- Xencor, Inc.
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02476617
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 25 people
- Sponsor
- AbbVie
HCV Infection
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of…
- Trial name
- NCT00890318
- Testing
- ABT-072, ketoconazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Abbott
Crohn Disease
Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC
The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's…
- Trial name
- NCT00094458
- Testing
- infliximab (IFX) infusion; azathioprine (AZA) caps
- Where
- 115 sites in United States, Austria and 13 more
- Volunteers
- 508 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251758
- Testing
- Dexlansoprazole MR
- Where
- 99 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Ulcerative Colitis
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy
The objective of this study is to evaluate the efficacy and the tolerability of oral parnaparin sodium (210mg), administered in extended-release tablets identified as CB-01-05-MMX™.
- Trial name
- NCT00867438
- Testing
- Sigmoidoscopy
- Volunteers
- 133 people
- Sponsor
- Cosmo Technologies Ltd
Hepatitis C
A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects
This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals
- Trial name
- NCT02760758
- Testing
- CDI-31244
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Cocrystal Pharma, Inc.
Cancer Colon, Polyp of Colon
Clinical Trial Verifying C-REX LapAid and C-REX DMH/DMHC
In colorectal surgery, hand suturing and stapling are routine methods for performing intestinal anastomoses, and these methods appear to be similar in terms of clinical safety.
- Trial name
- NCT03179358
- Testing
- C-REX Ring-locking Procedure
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Carponovum AB
Hepatitis C, Chronic
Dose Ranging of GSK2336805 in Combination Therapy
GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being developed for the treatment of chronic HCV infection.
- Trial name
- HAI115879 (NCT01648140)
- Testing
- GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 286 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Cystic Fibrosis, Steatorrhea
An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption
The purpose of this study is to evaluate the effectiveness and safety of PANCREASE MT (pancrelipase microtablets) to improve steatorrhea (excessive excretion of fat in feces) in infants and toddlers with cystic fibrosis who have…
- Trial name
- NCT00217204
- Testing
- Pancrelipase microtablets
- Volunteers
- 18 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Liver Diseases
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
- Trial name
- NCT00382668
- Testing
- Dasatinib
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Gastrointestinal Stromal Tumors
Study for Patients Previously Treated in Avapritinib Clinical Trials
This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.
- Trial name
- NCT04825574
- Testing
- Avapritinib
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Blueprint Medicines Corporation
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic…
- Trial name
- ENIGMA 2 (NCT04322604)
- Testing
- lirentelimab (AK002)
- Where
- 60 sites in United States
- Volunteers
- 181 people
- Sponsor
- Allakos Inc.
Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
The purpose of this study is to evaluate efficacy and safety of ZYIL1 oral capsule twice a day for 12 weeks for treatment of mild to moderate active ulcerative colitis resistant or intolerant to oral aminosalicylates.
- Trial name
- NCT06398808
- Testing
- Arm1, Arm 2
- Where
- India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Eosinophilic Esophagitis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic…
- Trial name
- KRYPTOS (NCT04322708)
- Testing
- lirentelimab (AK002)
- Where
- 78 sites in United States, Australia and 1 more
- Volunteers
- 277 people
- Sponsor
- Allakos Inc.
Fecal Incontinence
Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers
This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.
- Trial name
- NCT01406925
- Testing
- NRL001 cream
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Norgine
Hepatic Insufficiency
Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects
To investigate the influence of mild, moderate, and severe liver impairment on the pharmacokinetics and pharmacodynamics of linagliptin in comparison with a control group with normal hepatic function after single or multiple oral…
- Trial name
- NCT02183376
- Testing
- BI 1356
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.